AI Science Tracker
EN

Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19.

Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, Wuhan Jinyintan Hospital, Wuhan, Hubei 430023, China; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences (CAS), Wuhan, Hubei 430071, China; Center for Translational Medicine, Wuhan Jinyintan Hospital, Wuhan, Hubei 430023, China · 20 Oct 2020 · medicine

Discovery

Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19.

Source check: Source checked. Not independent scientific confirmation.

Finding: It identifies 11 host proteins and specific multi-protein panels associated with severity/outcomes; e.g. a four-protein panel discriminated severity groups and a three-protein combination predicted severe/fatal outcome. Five-fold CV plus a separate proteomics cohort (n=26) and ELISA validation in additional samples. The article notes limited early-pandemic sample sizes and says biomarker mechanisms and therapeutic relevance require further work.

Technology: POC-19 uses penalized logistic regression with LASSO/ridge penalties to rank biomarker combinations from plasma proteomics.

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
POC-19 uses penalized logistic regression with LASSO/ridge penalties to rank biomarker combinations from plasma proteomics.
Test and result
It identifies 11 host proteins and specific multi-protein panels associated with severity/outcomes; e.g. a four-protein panel discriminated severity groups and a three-protein combination predicted severe/fatal outcome.
Limitation / still unknown
Five-fold CV plus a separate proteomics cohort (n=26) and ELISA validation in additional samples. The article notes limited early-pandemic sample sizes and says biomarker mechanisms and therapeutic relevance require further work.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC7574896/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 22 Nov 2026. Review scope: Full primary PMC article reviewed. The authors used plasma proteomics and their machine-learning POC-19 pipeline (penalized logistic regression with LASSO/ridge) to select protein biomarker combinations for COVID-19 severity/outcome; results were evaluated in a separate plasma cohort and by ELISA in another cohort. First online 2020-10-20. Neither catalog snapshot contains this DOI/title or the same POC-19 biomarker result..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.